Skip to main content

Table 2 Echocardiologic evaluation of cardiac function at 2 and 7 days after AAC

From: Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction

  2 days after AAC 7 days after AAC
Sham AAC AAC + TMZ P values Sham AAC AAC + TMZ P values
IVSd (mm) 0.95 ± 0.12 1.00 ± 0.05 1.01 ± 0.06 >0.05 1.10 ± 0.03 1.21 ± 0.07 1.24 ± 0.11 >0.05
LVPWd (mm) 1.30 ± 0.40 1.63 ± 0.07 1.64 ± 0.04 >0.05 1.45 ± 0.19 1.67 ± 0.12 1.65 ± 0.23 >0.05
LVEDD (mm) 4.30 ± 0.27 4.53 ± 0.39 4.52 ± 0.26 >0.05 4.50 ± 0.28 4.90 ± 0.09 5.03 ± 0.12 >0.05
LVESD (mm) 2.46 ± 0.11 2.52 ± 0.09 2.51 ± 0.07 >0.05 2.49 ± 0.07 2.62 ± 0.24 2.64 ± 0.18 >0.05
LVFS (%) 37.97 ± 9.05 44.66 ± 10.04 45.27 ± 8.13 >0.05 38.63 ± 8.15 44.56 ± 1.89 43.68 ± 2.78 >0.05
LVEF (%) 73.47 ± 10.51 85.40 ± 1.91 84.23 ± 2.32 >0.05 79.5 ± 3.41 86.09 ± 3.19 84.48 ± 2.67 >0.05
  1. Data are presented as mean ± SD, n = 6 per group
  2. AAC aortic artery constriction, IVSd interventricular septal thickness at end diastole, LVPWd left ventricular posterior wall thickness at end diastole, LVEDD left ventricular end-diastolic dimension, LVESD left ventricular end-systolic dimension, LVFS left ventricular factional shortening, LVEF left ventricular ejection fraction, TMZ trimetazidine